UroGen Pharma Ltd (NASDAQ: URGN) closed the day trading at $14.33 down -17.97% from the previous closing price of $17.47. In other words, the price has decreased by -$3.14 from its previous closing price. On the day, 620519 shares were traded.
Ratios:
For a better understanding of URGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.87 and its Current Ratio is at 7.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 08, 2023, Downgraded its rating to Hold and sets its target price to $10 from $35 previously.
On April 27, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $20.
H.C. Wainwright reiterated its Buy rating for the stock on April 16, 2020, while the target price for the stock was revised from $53 to $57.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 ’24 when Smith Jason Drew sold 4,993 shares for $15.74 per share. The transaction valued at 78,590 led to the insider holds 18,824 shares of the business.
Schoenberg Mark sold 3,789 shares of URGN for $59,639 on Jan 31 ’24. The Chief Medical Officer now owns 149,423 shares after completing the transaction at $15.74 per share. On Aug 31 ’23, another insider, Smith Jason Drew, who serves as the General Counsel of the company, sold 3,800 shares for $18.01 each. As a result, the insider received 68,438 and left with 18,407 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 442.31M and an Enterprise Value of 394.44M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.71. Its current Enterprise Value per Revenue stands at 5.10 whereas that against EBITDA is -4.47.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $24.13, while it has fallen to a 52-week low of $7.75. The 50-Day Moving Average of the stock is 16.61, while the 200-Day Moving Average is calculated to be 14.64.
Shares Statistics:
Over the past 3-months, URGN traded about 314.36K shares per day on average, while over the past 10 days, URGN traded about 298.65k shares per day. A total of 30.81M shares are outstanding, with a floating share count of 25.44M. Insiders hold about 17.42% of the company’s shares, while institutions hold 79.76% stake in the company. Shares short for URGN as of Feb 29, 2024 were 3.93M with a Short Ratio of 12.52, compared to 3.26M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.75% and a Short% of Float of 13.92%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.68 for the current quarter, with a high estimate of -$0.61 and a low estimate of -$0.74, while EPS last year was -$1.22. The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.58 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$3.43 and -$3.66 for the fiscal current year, implying an average EPS of -$3.56. EPS for the following year is -$2.63, with 5 analysts recommending between -$1.93 and -$3.24.
Revenue Estimates
5 analysts predict $22.57M in revenue for the current quarter. It ranges from a high estimate of $24.54M to a low estimate of $21.51M. As of the current estimate, UroGen Pharma Ltd’s year-ago sales were $18.09M, an estimated increase of 24.80% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $22.32M, an increase of 29.90% over than the figure of $24.80% in the same quarter last year. There is a high estimate of $24.3M for the next quarter, whereas the lowest estimate is $19M.
A total of 5 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $83.73M, while the lowest revenue estimate was $80.69M, resulting in an average revenue estimate of $81.75M. In the same quarter a year ago, actual revenue was $64.36M, up 27.00% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $108.7M in the next fiscal year. The high estimate is $115.83M and the low estimate is $97.86M. The average revenue growth estimate for next year is up 33.00% from the average revenue estimate for this year.
